Mike Foote

New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

@acpmpresearch @mskcc Thank you so much to the ACPMP and supporters for this great honor! We can’t wait to get started on finding new treatments for our patients.

We are proud to announce @MikeFooteMD of @MSKCC as the first-ever recipient of our $150K ACPMP Changemaker Research Grant for his research project, “Targeting the Surface Proteome of Appendiceal Cancer Peritoneal Metastasis.” This research is made possible by our donors!🎗️

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer” footnote. 📘 Clear frameworks for diagnosis, staging, and management 🔍 Recognition that appendiceal primaries are biologically distinct 💡 Emphasis on multidisciplinary care and the need for more trials Only downside? @jpshen_md and Michael Foote — two of the biggest names in this space — weren’t listed as contributors. Still, a huge step forward for patients and clinicians who’ve long been navigating in the dark. The field is finally getting the structure it deserves. nccn.org/professionals/… @OncoAlert @TheGutOncLab #GIOncology #AppendicealCancer @acpmpresearch

Father and son enjoying #ESMO25 in Berlin!!

Exciting research is ahead at #ESMO25! Tomorrow, @MikeFooteMD will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @MSKCancerCenter @myESMO Learn more: bit.ly/4qrq3Rg

🌟Therapeutic Targeting of MMR-Deficient Cancers🌟 🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian, @MikeFooteMD @MSKCancerCenter @ldiaz1971 @NatureRevCancer @Nature @OncoAlert “MMRd tumors: an immunogenic paradox — vulnerable yet resilient” 🔵 Immune-checkpoint inhibitors (ICIs) provide durable responses in many MMRd/MSI-H tumors, regardless of tumor origin 🔵 These tumors harbor frameshift mutations → neoantigens → high immunogenicity 🔵 Strong TILs, checkpoint expression & molecular profile contribute to ICI sensitivity 🔵 Yet, not all MMRd tumors respond and many acquire resistance 🔵 Review explores biology, genomic sequelae, epidemiology & therapeutic strategies 🔵 Highlights emerging biomarkers, resistance mechanisms & future directions 💡 A must-read synthesis connecting tumor genomics with immunotherapy impact #MSI #MMRd #Immunotherapy #ICIs #CancerBiomarkers #OncoImmunology #TumorMicroenvironment #DNARepair #Oncology #CancerResearch #OncoTwitter nature.com/articles/s4157…

Very excited about our work with 60+ collaborators across the world to define algorithms for management of patients with peritoneal disease! acsjournals.onlinelibrary.wiley.com/doi/abs/10.100…

@SchultzKurt @MikeWach_MD @ardamanshergill @MikeFooteMD and many others! @YaleMed @MoffittNews @UofC @MSKCancerCenter #cancer #peritoneum #colorectalcancer #cancerreserach

So excited for Benoit Rousseau’s paper in Cancer Cell describing mutagenic chemo combinations to make cold tumors hot! cell.com/cancer-cell/ab…

🚨 New research from @ASCO: A clinical trial led by @YJanjigianMD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the #esophagus and gastroesophageal junction (#GEJ). “For gastroesophageal cancer patients to go through surgery and chemo, it’s devastating to have a recurrence of the cancer,” says Dr. Janjigian. “This trial shows that adding immunotherapy to chemo before and after surgery can dramatically improve the chance that cancer won’t return.” Learn more about how these results offer new hope to people facing this diagnosis, which is the fifth most common cancer worldwide: bit.ly/45Cxpcu #ASCO25

Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

New paper from our team at @MSKCancerCenter. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NE…

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  @AACR

An approach pioneered at MSK that caused #rectalcancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric), colon, esophageal, urothelial, and others. Gastrointestinal oncologist @AndreaCercek presented the results from a larger clinical trial at #AACR25. The new results saw 80% of patients with several types of cancer successfully treated with only #immunotherapy. “This is very exciting and shows that a broad range of tumors with this genetic mutation called MMRd can be treated with immunotherapy replacing surgery and radiation, giving patients better quality of life." Learn more: bit.ly/3GvgqP2 #AACR25 @AACR

New research presented by MSK gastrointestinal medical oncologist @YJanjigianMD at #AACR25 shows that a simple blood test can help doctors identify which patients are most likely to benefit from #immunotherapy after cancer surgery to remove tumors — potentially preventing the disease from coming back. “This could change how we think about treating early-stage cancers,” Dr. Janjigian says. “We’re not just trying to treat what we can see. We’re trying to intercept the disease before it has a chance to grow.” @AACR Learn more: bit.ly/433DQ6K

ICYMI: @jpshen_md of @MDAndersonNews and @MikeFooteMD of @MSKCancerCenter discuss how appendix cancer differs from CRC and examine new potential targeted treatments: brnw.ch/21wS5hM #ASCODailyNews

New research by @jpshen_md & @MikeFooteMD reveals that #appendixcancer is distinct from colorectal cancer, requiring different treatment approaches. Promising trials explore targeted therapies for better outcomes. Learn more: dailynews.ascopubs.org/do/appendix-ca…

Fascinating study by Benoit Rousseau and @ldiaz1971 examining the duration of immune checkpoint blockade in MMRD early stage tumors. Six months seems to be the magic number for complete response rate!

Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors: brnw.ch/21wLYNy @MikeFooteMD #gicsm